BR112019000657A2 - método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna - Google Patents

método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna

Info

Publication number
BR112019000657A2
BR112019000657A2 BR112019000657-5A BR112019000657A BR112019000657A2 BR 112019000657 A2 BR112019000657 A2 BR 112019000657A2 BR 112019000657 A BR112019000657 A BR 112019000657A BR 112019000657 A2 BR112019000657 A2 BR 112019000657A2
Authority
BR
Brazil
Prior art keywords
dna vaccine
cancer immunotherapy
dna
produce
present
Prior art date
Application number
BR112019000657-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Lubenau Heinz
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of BR112019000657A2 publication Critical patent/BR112019000657A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019000657-5A 2016-07-13 2017-07-12 método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna BR112019000657A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001550.9 2016-07-13
EP16001550 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
BR112019000657A2 true BR112019000657A2 (pt) 2019-04-24

Family

ID=56418345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000657-5A BR112019000657A2 (pt) 2016-07-13 2017-07-12 método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna

Country Status (13)

Country Link
US (2) US10821163B2 (https=)
EP (1) EP3484503A1 (https=)
JP (2) JP7098599B2 (https=)
KR (3) KR20190027834A (https=)
CN (1) CN109475614A (https=)
AU (1) AU2017295004B2 (https=)
BR (1) BR112019000657A2 (https=)
CA (1) CA3028549A1 (https=)
IL (1) IL263568A (https=)
MX (1) MX2019000415A (https=)
RU (1) RU2019100079A (https=)
SG (1) SG11201811258UA (https=)
WO (1) WO2018011289A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用dnaワクチンを標的とするネオアンチゲン
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230121528A1 (en) 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
WO2024005122A1 (ja) * 2022-06-30 2024-01-04 株式会社島津製作所 微生物の分析の準備方法、および、微生物の分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
CA2853656C (en) * 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
JP6325534B2 (ja) 2012-07-05 2018-05-16 バクシム アクチェンゲゼルシャフト 膵臓癌患者用dnaワクチン
MX364922B (es) * 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
SI3082850T1 (sl) * 2013-12-18 2020-01-31 Vaximm Gmbh DNA cepivo, ki cilja MSLN za imunoterapijo raka
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법

Also Published As

Publication number Publication date
AU2017295004B2 (en) 2020-08-13
EP3484503A1 (en) 2019-05-22
AU2017295004A1 (en) 2019-01-03
RU2019100079A (ru) 2020-08-13
US11590215B2 (en) 2023-02-28
KR20190027834A (ko) 2019-03-15
WO2018011289A1 (en) 2018-01-18
JP2022097591A (ja) 2022-06-30
JP2019521154A (ja) 2019-07-25
JP7098599B2 (ja) 2022-07-11
US10821163B2 (en) 2020-11-03
US20190183996A1 (en) 2019-06-20
CN109475614A (zh) 2019-03-15
IL263568A (en) 2019-01-31
KR20230079514A (ko) 2023-06-07
CA3028549A1 (en) 2018-01-18
SG11201811258UA (en) 2019-01-30
US20220072112A1 (en) 2022-03-10
MX2019000415A (es) 2019-03-28
KR20260047288A (ko) 2026-04-07

Similar Documents

Publication Publication Date Title
BR112019000657A2 (pt) método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
CL2021001506A1 (es) Anticuerpos que se unen a cd3
CO2020008940A2 (es) Anticuerpos de unión a gprc5d
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
CL2024000802A1 (es) Anticuerpos que se fijan a gprc5d
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
EA201890028A1 (ru) Антитело, связывающее cd3 человека
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
MX384138B (es) Anticuerpos anti-c5 y métodos para su uso.
WO2019122052A3 (en) Antibodies binding to hla-a2/wt1
BR112019002579A2 (pt) anticorpos biespecíficos fab monovalentes, assimétricos e tandem
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
BR112017010298A2 (pt) anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
CL2015002705A1 (es) Anticuerpos anti-cd52.
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
WO2019227106A9 (en) Tumor-specific neoantigens and methods of using the same
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
AR124957A2 (es) Fragmentos de anticuerpos con bisagra modificada y métodos de preparación de los mismos
AR133126A2 (es) Fragmentos de anticuerpos con bisagra modificada y métodos de preparación de los mismos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]